Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights

02.08.2023 - – Net revenue rose 81% from prior quarter to $58.7 million –– CIMERLI net sales quadrupled to $26.7 million compared to prior quarter –– UDENYCA autoinjector launched in late May, and YUSIMRY launched in July –– Planned merger with Surface Oncology ...

Related Keywords

China ,Canada ,United States ,American ,Junshi Biosciences ,Jodi Sievers ,Denny Lanfear ,Klinge Pharma ,Coherus Biosciences ,Marek Ciszewski ,Corporate Communications ,Drug Administration ,Surface Oncology Inc ,Amgen Inc ,Exchange Commission On ,American Society Of Clinical Oncology ,Genentech Inc ,Exchange Commission ,Abbvie Inc ,Coherus Biosciences Inc ,American Society ,Clinical Oncology ,Novel Immuno Oncology Pipeline ,Surface Oncology ,Investigational New Drug ,Coheru Chairman ,Chief Executive ,Forward Looking Statements ,Biologics License Application ,Securities Litigation Reform Act ,Coheru Quarterly Report ,Contact Information ,Consolidated Statements ,Public Offering ,